Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit. Overview We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endog...
Q2 FY2026 — expected 2026-08-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001867096-26-000016 | EDGAR | 90K words |
| 2025-03-06 | 2024-12-31 | 0001867096-25-000039 | EDGAR | — |
| 2024-03-06 | 2023-12-31 | 0001867096-24-000031 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001867096-23-000031 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001867096-22-000040 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001867096-25-000159 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001867096-25-000136 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001867096-25-000089 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001867096-24-000187 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001867096-24-000162 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001867096-24-000065 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001867096-23-000139 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001867096-23-000114 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001867096-23-000069 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001867096-22-000127 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001867096-22-000107 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001867096-22-000063 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001867096-26-000012 | EDGAR | 4K words |
| 2026-02-27 | 0001867096-26-000010 | EDGAR | — |
| 2026-01-08 | 0001867096-26-000004 | EDGAR | — |
| 2025-12-01 | 0001867096-25-000161 | EDGAR | — |
| 2025-11-06 | 0001867096-25-000156 | EDGAR | — |
| 2025-08-07 | 0001867096-25-000130 | EDGAR | — |
| 2025-06-04 | 0001867096-25-000104 | EDGAR | — |
| 2025-06-03 | 0001867096-25-000100 | EDGAR | — |
| 2025-05-08 | 0001867096-25-000085 | EDGAR | — |
| 2025-03-28 | 0001867096-25-000054 | EDGAR | — |
73 total filings indexed. 46 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001867096 |
| Ticker | XERS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.xerispharma.com |
| Listed | 2018-06-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report